Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics
Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.
Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.
In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.
ESM
Related news
Purina targets food waste by using surplus brewery grains in dog treat pilot
Purina today launches a new dog treat formulated with nutritious…
Read more >USAID Partners with Nestlé to Boost Low-Carbon Coffee Production in Southeast Asia
The United States Agency for International Development (USAID) Green Invest…
Read more >Nestlé is expanding its portfolio with vegan and vegetarian meat alternatives
Nestlé’s plant-based Garden Gourmet product line is also available in…
Read more >Related news
Overall satisfaction with retailers falls
Overall customer satisfaction with large grocery chains dropped significantly in…
Read more >Magazine: 2021: Change is here to be solidified
In 2020 we stopped flying and most likely the trend…
Read more >Purina targets food waste by using surplus brewery grains in dog treat pilot
Purina today launches a new dog treat formulated with nutritious…
Read more >